Industry Research Reports and Market Analysis at MindBranch.com
  

Animal Pharm's Top 20: 2006 edition

Product Type: Market Research Report
Published by: Informa Healthcare
Published: October 2006
Product Code: R3535-43
Description
Animal Pharm’s Top 20 is recognised throughout the animal health and nutrition industry as a key source of information and analysis on the 20 largest companies in the sector. Invest in this report to keep informed of the performance of your potential competitors, collaborators or customers.

Key Findings:
  • Global sales of animal health and nutrition products totalled almost US$21.7 billion in 2005. That figure was around 7% higher than the year-earlier total of US$20.3 billion.
  • Sales of veterinary pharmaceuticals and biologicals for use in small animals alone are now worth almost US$6 billion, a figure equivalent to more than 27% of the entire market.
  • The 13% increase in revenues reported by Pfizer Animal Health in 2005 saw the company consolidate its position at the head of the global sales league, with a gap of more than US$200 million between it and second-placed Merial.
  • Merial appears set to leapfrog Pfizer in 2006, regaining the leadership position it held prior to Pfizer’s acquisition of Pharmacia Corp in 2003.
  • The acquisition of Adisseo by the China National Chemical Corp (CNCC), announced late in 2005 and completed in 2006, is among the most significant M&A developments reported recently in the industry.
  • Despite SPAH’s recent problems in the US market, most recent results indicate that the worst may finally be behind the company, with US sales up sharply on year-earlier figures in the first half of 2006.
  • Merial’s Frontline sales fell back by 11% on year-earlier figures in the third quarter of 2005. That was followed by a 31% gain in the final quarter, however, and further strong growth through the first half of 2006.

Table of Contents
CHAPTER 1 INTRODUCTION
1.1 The world market for animal health and nutrition products
1.1.1 Market shares by region
1.1.2 Market shares by product category
1.1.3 Market shares by species
1.2 The animal health and nutrition products industry
1.2.1 Leading companies in the animal health and nutrition sector
1.2.1.1 Market leaders in 2005
1.2.1.2 Market leaders in 2006
1.2.2 Industry profit levels
1.3 Currencies and exchange rates used in this report
CHAPTER 2 ADISSEO
2.1 Company background
2.2 Animal nutrition sales
2.2.1 2004 performance
2.2.2 2005 performance
2.2.3 Interim 2006 performance
2.3 Geography of the business
2.3.1 Europe, Middle East, Africa and CIS
2.3.2 Asia/Pacific
2.3.3 Latin America
2.3.4 North America
2.4 Product portfolio
2.4.1 Methionine
2.4.2 Vitamins
2.4.3 Enzymes
2.5 R&D
2.6 Strategy
2.7 Prospects
CHAPTER 3 ALPHARMA
3.1 Company background
3.2 Animal health sales and operating profit
3.2.1 2004 performance
3.2.2 2005 performance
3.2.3 Interim 2006 performance
3.3 Geography of the business
3.3.1 US
3.3.2 International markets
3.4 Product portfolio
3.4.1 Antibiotics
3.4.2 Anticoccidials
3.4.3 Antibacterials
3.4.4 Other products
3.5 R&D
3.6 Strategy
3.7 Prospects
CHAPTER 4 BASF
4.1 Company background
4.2 Animal nutrition sales
4.2.1 2004 performance
4.2.2 2005 performance
4.2.3 Interim 2006 performance
4.3 Geography of the business
4.3.1 Europe
4.3.2 Americas
4.3.3 Asia/Pacific
4.4 Product portfolio
4.4.1 Vitamins
4.4.2 Amino acids
4.4.3 Carotenoids
4.4.4 Enzymes
4.4.5 Other products
4.5 R&D
4.6 Strategy
4.7 Prospects
CHAPTER 5 BAYER
5.1 Company background
5.2 Animal health sales and operating income
5.2.1 2004 performance
5.2.2 2005 performance
5.2.3 Interim 2006 performance
5.3 Geography of the business
5.3.1 North America
5.3.2 Europe
5.3.3 Asia/Pacific
5.3.4 Latin America, Africa & Middle East
5.4 Product portfolio
5.4.1 Antiparasitics
5.4.2 Antimicrobials
5.4.3 Other products
5.5 R&D
5.6 Strategy
5.7 Prospects
CHAPTER 6 BOEHRINGER INGELHEIM
6.1 Company background
6.2 Animal health sales
6.2.1 2004 performance
6.2.2 2005 performance
6.2.3 Interim 2006 performance
6.3 Geography of the business
6.3.1 Europe
6.3.2 North America
6.3.3 Other markets
6.4 Product portfolio
6.4.1 Pharmaceuticals
6.4.2 Biologicals
6.4.3 Other products
6.5 R&D
6.6 Strategy
6.7 Prospects
CHAPTER 7 CEVA
7.1 Company background
7.2 Animal health sales and earnings
7.2.1 2004 performance
7.2.2 2005 performance
7.2.3 Interim 2006 performance
7.3 Geography of the business
7.3.1 Europe
7.3.2 International markets
7.4 Product portfolio
7.4.1 Companion animal and behavioral products
7.4.2 Reproductive controls
7.4.3 Anti-infectives
7.4.4 Vaccines
7.4.5 Others
7.5 R&D
7.6 Strategy
7.7 Prospects
CHAPTER 8 DAINIPPON SUMITOMO PHARMA
8.1 Company background
8.2 Animal health sales and operating profit
8.2.1 Fiscal 2005 performance
8.2.2 Fiscal 2006 performance
8.3 Geography of the business
8.4 Product portfolio
8.4.1 Companion animal products
8.4.2 Food animal products
8.5 R&D
8.6 Strategy
8.7 Prospects
CHAPTER 9 DEGUSSA
9.1 Company background
9.2 Feed additive sales
9.2.1 2004 performance
9.2.2 2005 performance
9.2.3 Interim 2006 performance
9.3 Geography of the business
9.4 Product portfolio
9.4.1 Methionine
9.4.2 Other amino acids
9.5 R&D
9.6 Strategy
9.7 Prospects
CHAPTER 10 DSM
10.1 Company background
10.2 Animal nutrition sales
10.2.1 2004 performance
10.2.2 2005 performance
10.2.3 Interim 2006 performance
10.3 Geography of the business
10.4 Product portfolio
10.4.1 Vitamins
10.4.2 Carotenoids
10.4.3 Feed enzymes
10.4.4 Other products
10.5 R&D
10.6 Strategy
10.7 Prospects
CHAPTER 11 ELANCO
11.1 Company background
11.2 Animal health sales and operating income
11.2.1 2004 performance
11.2.2 2005 performance
11.2.3 Interim 2006 performance
11.3 Geography of the business
11.3.1 US
11.3.2 International markets
11.4 Product portfolio
11.4.1 Tylosin
11.4.2 Tilmicosin
11.4.3 Monensin
11.4.4 Avilamycin
11.4.5 Ractopamine
11.4.6 Other products
11.5 R&D
11.6 Strategy
11.7 Prospects
CHAPTER 12 FORT DODGE
12.1 Company background
12.2 Animal health sales and operating profit
12.2.1 2004 performance
12.2.2 2005 performance
12.2.3 Interim 2006 performance
12.3 Geography of the business
12.3.1 US
12.3.2 International markets
12.4 Product portfolio
12.4.1 Biologicals
12.4.2 Antiparasitics
12.4.3 Other pharmaceuticals
12.5 R&D
12.6 Strategy
12.7 Prospects
CHAPTER 13 IDEXX
13.1 Company background
13.2 Sales and income
13.2.1 2004 performance
13.2.2 2005 performance
13.2.3 Interim 2006 performance
13.3 Geography of the business
13.3.1 North America
13.3.2 International markets
13.4 Product portfolio
13.4.1 Companion animal group
13.4.1.1 Immunoassays
13.4.1.2 Veterinary instrument systems
13.4.1.3 Reference laboratory and consulting services
13.4.1.4 Information management and radiography
13.4.1.5 Veterinary pharmaceuticals
13.4.2 Water products and services
13.4.3 Food diagnostics group
13.5 R&D
13.6 Strategy
13.7 Prospects
CHAPTER 14 INTERVET
14.1 Company background
14.2 Animal health sales and operating profit
14.2.1 2004 performance
14.2.2 2005 performance
14.2.3 Interim 2006 performance
14.3 Geography of the business
14.3.1 Europe
14.3.2 Americas
14.3.3 Other markets
14.4 Product portfolio
14.4.1 Biologicals
14.4.2 Antiparasitics
14.4.3 Anti-infectives
14.4.4 Other products
14.5 R&D
14.6 Strategy
14.7 Prospects
CHAPTER 15 MERIAL
15.1 Company background
15.2 Animal health sales
15.2.1 2004 performance
15.2.2 2005 performance
15.2.3 Interim 2006 performance
15.3 Geography of the business
15.3.1 US
15.3.2 Europe
15.3.3 International
15.4 Product portfolio
15.4.1 Avermectins
15.4.2 Fipronil
15.4.3 Biologicals
15.4.4 Other products
15.5 R&D
15.6 Strategy
15.7 Prospects
CHAPTER 16 NOVARTIS
16.1 Company background
16.2 Animal health sales and operating profit
16.2.1 2004 performance
16.2.2 2005 performance
16.2.3 Interim 2006 performance
16.3 Geography of the business
16.3.1 North America
16.3.2 Europe
16.3.3 Other markets
16.4 Product portfolio
16.4.1 Antiparasitics
16.4.2 Anti-infectives
16.4.3 Other pharmaceuticals
16.4.4 Vaccines
16.5 R&D
16.6 Strategy
16.7 Prospects
CHAPTER 17 PFIZER
17.1 Company background
17.2 Animal health sales and operating profit
17.2.1 2004 performance
17.2.2 2005 performance
17.2.3 Interim 2006 performance
17.3 Geography of the business
17.3.1 US
17.3.2 International markets
17.4 Product portfolio
17.4.1 Anti-infectives
17.4.2 Antiparasitics
17.4.3 Vaccines
17.4.4 Other pharmaceuticals
17.5 R&D
17.6 Strategy
17.7 Prospects
CHAPTER 18 PHIBRO
18.1 Company background
18.2 Animal health & nutrition sales and operating profit
18.2.1 Fiscal 2004 performance
18.2.2 Fiscal 2005 performance
18.2.3 Interim fiscal 2006 performance
18.3 Geography of the business
18.4 Product portfolio
18.4.1 Phibro Animal Health
18.4.2 Koffolk
18.4.3 Prince Agri Products
18.5 R&D
18.6 Strategy
18.7 Prospects
CHAPTER 19 SCHERING-PLOUGH
19.1 Company background
19.2 Animal health sales and earnings
19.2.1 2004 performance
19.2.2 2005 performance
19.2.3 Interim 2006 performance
19.3 Geography of the business
19.3.1 US
19.3.2 International markets
19.4 Product portfolio
19.4.1 Antiparasitics
19.4.2 Anti-infectives
19.4.3 Vaccines
19.4.4 Other products
19.5 R&D
19.6 Strategy
19.7 Prospects
CHAPTER 20 VETOQUINOL
20.1 Company background
20.2 Animal health sales
20.2.1 2004 performance
20.2.2 2005 performance
20.2.3 Interim 2006 performance
20.3 Geography of the business
20.3.1 Europe
20.3.2 North America
20.3.3 Other markets
20.4 Product portfolio
20.4.1 Anti-infectives
20.4.2 Other pharmaceuticals
20.4.3 Other products
20.5 R&D
20.6 Strategy
20.7 Prospects
CHAPTER 21 VIRBAC
21.1 Company background
21.2 Animal health sales and operating profit
21.2.1 2004 performance
21.2.2 2005 performance
21.2.3 Interim 2006 performance
21.3 Geography of the business
21.3.1 Europe
21.3.2 North America
21.3.3 Other markets
21.4 Product portfolio
21.4.1 Antiparasitics
21.4.2 Anti-infectives
21.4.3 Biologicals
21.4.4 Other products
21.5 R&D
21.6 Strategy
21.7 Prospects
LIST OF TABLES
Table 1.1 Geography of the world market, 2005
Table 1.2 World market structure by product category, 2005
Table 1.3 World market structure by species, 2005
Table 1.4 Top 20 rankings, 2005
Table 1.5 Top 20 ranking forecasts, 2006
Table 1.6 Leading animal health company earnings in 2005
Table 2.1 Adisseo animal nutrition sales, 2001-2005
Table 2.2 Adisseo sales by region, 2005
Table 3.1 Alpharma's revenues by division, 2005
Table 3.2 Alpharma animal health sales, 2001-2005
Table 3.3 Alpharma animal health earnings and margins, 2001-2005
Table 3.4 Alpharma first half sales, 2005 and 2006
Table 3.5 Alpharma's major product sales, 2005
Table 4.1 BASF sales by operating segment, 2005
Table 4.2 BASF animal nutrition sales, 2001-2005
Table 5.1 Bayer sales by operating segment, 2005
Table 5.2 Bayer animal health sales, 2001-2005
Table 5.3 Bayer animal health earnings and margins, 2001-2005
Table 5.4 Bayer's first half sales, 2005-2006
Table 5.5 Bayer animal health sales by region, 2005
Table 5.6 Bayer animal health sales by species segment, 2004 and 2005
Table 5.7 Bayer's imidacloprid sales, 2001-2005
Table 5.8 Bayer animal health research spending, 2001-2005
Table 5.9 Bayer's late-stage development pipeline
Table 6.1 Boehringer Ingelheim sales by business area, 2005
Table 6.2 BIV sales, 2001-2004
Table 6.3 BIV sales by region, 2005
Table 6.4 Sales of key BIV pharmaceutical brands
Table 6.5 BIV spending on R&D, 2001-2005
Table 7.1 Ceva animal health sales, 2001-2005
Table 7.2 Ceva earnings and operating margins, 2001-2005
Table 7.3 Ceva's first half sales, 2005 and 2006
Table 7.4 Ceva animal health sales by region, 2005 1
Table 7.5 Ceva animal health sales by species, 2005 1
Table 8.1 DSP sales by business segment, fiscal 2006 1
Table 8.2 DSP Animal Science sales, fiscal 2002-2006 1
Table 8.3 DSP Animal Science sales by product sector, fiscal 2006 1
Table 9.1 Degussa sales by operating segment, 2005
Table 9.2 Degussa feed additive sales, 2001-2005
Table 10.1 DSM sales by operating segment, 2005
Table 11.1 Elanco's animal health sales, 2001-2005
Table 11.2 Elanco's operating income and margin, 2001-2005
Table 11.3 Elanco's interim 2006 sales performance
Table 11.4 Elanco's US/international sales split, 2001-2005
Table 12.1 Wyeth sales by operating segment, 2005
Table 12.2 Fort Dodge animal health sales, 2001-2005
Table 12.3 Fort Dodge operating income and margins, 2001-2005
Table 12.4 Fort Dodge first half sales, 2005-2006
Table 12.5 Fort Dodge US/international sales split, 2001-2005
Table 12.6 Fort Dodge sales by species, 2005
Table 13.1 Idexx sales, 2001-2005
Table 13.2 Idexx earnings and operating margin, 2001-2005
Table 13.3 Idexx first half sales, 2005 and 2006
Table 13.4 Idexx sales by region, 2005
Table 13.5 Idexx sales by operating segment, 2005
Table 13.6 Companion animal group revenues by business area
Table 13.7 Idexx spending on R&D, 2001-2005
Table 14.1 Akzo Nobel sales by operating segment, 2005
Table 14.2 Intervet animal health sales, 2001-2005
Table 14.3 Intervet's first half sales, 2005 and 2006
Table 14.4 Intervet sales by region, 2005
Table 14.5 Intervet sales by product segment, 2005
Table 15.1 Merial animal health sales, 2001-2005
Table 15.2 Merial first half animal health sales, 2005 and 2006
Table 15.3 Merial sales by product category, 2005
Table 15.4 Merial's avermectin revenues, 2001-2005
Table 15.5 Leading formulations in the Merial ivermectin range
Table 15.6 Fipronil sales, 2001-2005
Table 16.1 Novartis sales by operating segment, 2005
Table 16.2 Novartis animal health sales, 2001-2005
Table 16.3 Novartis animal health sales by region, 2005
Table 16.4 Novartis animal health sales by product segment, 2005
Table 17.1 Pfizer sales by operating segment, 2005
Table 17.2 Pfizer animal health sales, 2001-2005
Table 17.3 Pfizer animal health operating profit and margins, 2001-2005
Table 17.4 Pfizer first half animal health sales, 2005 and 2006
Table 17.5 Pfizer's US/international sales split, 2004 and 2005
Table 17.6 Pfizer animal health sales by species segment, 2004 and 2005
Table 17.7 Recent additions to the Pfizer anti-infectives range
Table 18.1 PAHC sales by operating segment, fiscal 2005 1
Table 18.2 PAHC animal health and nutrition sales, fiscal 2001-2005 1
Table 18.3 PAHC interim animal health sales, fiscal 2006 1
Table 18.4 PAHC animal health and nutrition sales by product category, fiscal 2005 1
Table 19.1 Schering-Plough sales by business sector, 2005
Table 19.2 SPAH sales, 2001-2005
Table 19.3 SPAH earnings and divisional margins, 2001-2005
Table 19.4 SPAH first half sales, 2005 and 2006
Table 19.5 SPAH's US/international sales split, 2004 and 2005
Table 20.1 Vétoquinol sales, 2001-2005
Table 20.2 Vétoquinol sales by region, 2005
Table 20.3 Vétoquinol's key acquisitions
Table 20.4 Vétoquinol sales by product category, 2005
Table 21.1 Virbac animal health sales, 2001-2005
Table 21.2 Virbac first half sales, 2005 and 2006
Table 21.3 Virbac sales by region, 2005
Table 21.4 Virbac sales by product segment, 2005
Ordering and More Information
Price and Delivery Options


MindBranch has been the leading provider of industry and investment research from more than 550 independent research firms since 1992. With over 90,000 market research reports, MindBranch is your trusted source of competitive business intelligence.